This invention provides specifically formulated LFA-I antagonists or pharmaceutically acceptable salts thereof that are suitable for topical delivery. In particular, the LFA-I antagonists are particularly well suited for localized treatment by having a rapid systemic clearance rate. The invention also encompasses methods of treatment and prevention of immune related disorders using the LFA-I topical formulations of the present invention.